1. Pink Sheet

Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning

 
• By Brenda Sandburg

The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.

Eye drop compounding
The US FDA objects to promotions for a compounded eye drop product. • Source: Shutterstock

The pharmaceutical compounding company ImprimisRx LLC has once again run afoul of the US Food and Drug Administration for misleading promotions about one of its products.

The agency’s Division of Pharmaceutical Quality Operations IV sent the company a warning letter in June objecting to claims made about its compounded eye drop product Pred-Moxi-Brom (prednisolone acetate 1%, moxifloxacin 0.5%, and bromfenac 0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet